Post-Stroke Hemiplegia (Investigational Adjunct)

Patient Summary

Is this FDA-cleared for this use?

Not FDA-cleared for post-stroke hemiplegia. FDA cleared medicinal leeches only for venous congestion in microsurgical reconstruction (K040187, June 2004). Use for post-stroke hemiplegia is investigational.

What evidence exists?

Tier C (investigational). Only anecdotal reports; there are no randomized controlled trials. Evidence-based stroke rehabilitation per AHA/ASA guidelines: structured inpatient or outpatient rehabilitation, constraint-induced movement therapy, repetitive task training, mirror therapy, robot-assisted therapy, functional electrical stimulation, and botulinum toxin for spasticity. Antiplatelet (aspirin, clopidogrel) or anticoagulant therapy for secondary prevention. Statin, blood pressure control, and lifestyle modification.

Main risks

• Bleeding from bite sites for 6 to 24 hours after detachment, prolonged on antiplatelet or anticoagulant
• Severe bleeding risk on dual antiplatelet or anticoagulant therapy (post-stroke standard)
• Worsening of spasticity or neurogenic pain
• Local skin infection or, rarely, Aeromonas infection
• Allergic reaction to leech saliva (uncommon)
• Risk in patients with marginal cerebral perfusion (transient symptom worsening)
• Substitution for evidence-based rehabilitation and secondary prevention
• Delay of constraint-induced movement therapy, botulinum toxin for spasticity, or rehab milestones

Who should not consider this

• Patients on dual antiplatelet (aspirin + clopidogrel) or anticoagulant therapy (absolute contraindication)
• Patients within 3 months of acute stroke (recovery window — focus on rehab)
• Patients with severe spasticity or contracture requiring physiatry evaluation
• Patients with active depression, post-stroke psychiatric symptoms (treat first)
• Patients on anticoagulants, with hemophilia, or with severe anemia
• Patients who have not engaged with structured stroke rehabilitation

What to ask your clinician

• Am I engaged with structured outpatient stroke rehabilitation?
• Have I been offered constraint-induced movement therapy or robot-assisted therapy?
• Am I a candidate for botulinum toxin injection for spasticity?
• What are my current antiplatelet or anticoagulant therapies, and is the bleeding risk acceptable?
• What evidence specifically supports leech therapy for stroke recovery?
• Has my secondary prevention been optimized (statin, blood pressure, lifestyle)?
• What is the cost and is it covered by insurance? (typically not covered)

When to seek urgent care

• Sudden new weakness, numbness, slurred speech, or vision loss (possible recurrent stroke)
• Sudden severe headache (worst of life — rule out hemorrhage)
• Chest pain, shortness of breath (possible cardiac event)
• Severe bleeding from any site (anticoagulant overdose or interaction)
• Spreading redness, warmth, pus, or red streaks (cellulitis)
• Fever above 38.0 C / 100.4 F or chills
• Bleeding from a bite site lasting more than 24 hours
• Hives, facial or tongue swelling, throat tightness, or breathing difficulty